TMJ cartilage damage and why symptom relief is not enough

For many people with jaw joint pain, the real frustration is not a lack of treatment options — it is that the available options do not fix the underlying problem. Corticosteroid injections can quieten an inflamed TMJ, and hyaluronic acid can ease mechanical friction, but neither addresses the cartilage defect itself. Once the injection wears off, the structural damage that caused the symptoms remains.

That gap matters because TMJ osteoarthritis affects up to 16% of the general population, and the joint's articular disc — a thin plate of fibrous cartilage — has negligible capacity for self-repair. Unlike bone, it carries no blood supply, so the biochemical signals that ordinarily trigger healing after tissue injury simply cannot reach damaged areas.

Surgery is one route to structural repair, but approximately 80% of people with temporomandibular disorders manage without ever reaching an operating theatre. That leaves a large group whose cartilage is deteriorating and whose current treatments are palliative at best.

ChondroFiller injection — an injectable collagen scaffold placed under image guidance as an outpatient procedure — is being explored as a pathway aimed at that structural problem, specifically in focal, contained defects where the surrounding cartilage borders remain intact.

How a ChondroFiller injection works

The product itself is straightforward in principle, even if the biology is not. ChondroFiller® liquid — the collagen scaffold marketed as Liquid Cartilage™ — is an acellular, injectable Type I collagen material, CE-marked as a Class III medical device. It contains no living cells and no synthetic fillers: just purified structural protein in liquid form.

Once placed inside the joint space, the liquid gels within three to five minutes, forming a three-dimensional, sponge-like matrix that physically fills the focal defect. That matrix then acts as a chemotactic signal — it recruits the patient's own mesenchymal stem cells from surrounding tissue into the scaffold. Those recruited cells can differentiate into chondrocyte-like cells and begin laying down new repair matrix, a process known as acellular matrix-induced chondrogenesis. As repair tissue matures, the collagen scaffold biodegrades progressively, leaving no permanent foreign material behind.

Delivery is the other defining feature. The injection is placed under ultrasound or fluoroscopic guidance — no operating theatre, no general anaesthesia, no dry joint bed, no arthroscope. The procedure is carried out as an outpatient appointment under local anaesthesia, which substantially reduces the procedural burden compared with surgical cartilage repair. The gel sets inside the joint itself, which means the clinician's precision in placing the injection directly shapes how well the scaffold occupies the defect.

Why the TMJ is a plausible but technically demanding target

The strongest argument for applying ChondroFiller in the TMJ rests on a shared molecular characteristic. Both the injectable scaffold and the TMJ's fibrocartilaginous disc are predominantly Type I collagen in composition — which means the scaffold and host tissue share the same structural protein, supporting the case for cellular integration and recruitment at the repair site. What remains unconfirmed is whether the chemotactic stem-cell response documented in knee studies translates identically to a fibrocartilage environment, rather than the hyaline cartilage that underpins all existing clinical data.

That distinction carries technical implications as well as biological ones. The TMJ is a far smaller and narrower joint than the knee, making accurate image-guided cannula placement considerably more demanding. Precision in placing the scaffold matters — a gel that does not fully occupy a focal defect in a joint this confined cannot be expected to replicate the outcomes reported in knee series.

Biomechanical loading adds a further constraint. The jaw moves constantly during chewing, speech, and normal swallowing, subjecting any regenerating scaffold to repeated compression and shear throughout the maturation window — a challenge largely absent in post-procedure knee rehabilitation, where weight-bearing can be controlled and staged.

The preclinical evidence offers cautious support. A 2026 systematic review by Nedeljkovic et al. (PMC12938102) examined 39 in vivo animal studies of scaffold-based TMJ regeneration and found that collagen-based hydrogel scaffolds demonstrated favourable biocompatibility and supported fibrocartilaginous repair. Heterogeneity across experimental designs limits how directly those findings inform clinical application, but the biological signal is coherent with the rationale for a Type I collagen scaffold in this joint.

What the evidence currently shows — and where the gaps are

Four independent clinical investigations provide the clearest measure of what ChondroFiller achieves in practice. Across all four knee cartilage defect studies, IKDC score improvements consistently exceeded the minimum clinically important difference of 16.7 points — the threshold above which patients report a meaningfully better outcome. The Jerosch et al. post-market clinical follow-up study, the most rigorous of the four, recorded a mean IKDC gain of 32.4 points sustained at three-year follow-up, with patients reaching a functional score of 80. These are not short-term symptom scores; they reflect durable functional recovery.

Structural repair data reinforce the picture. MRI-based MOCART scores in European studies ranged from 81.6 to 84.3, indicating greater than 80% defect filling and good integration with surrounding native cartilage. Scores progressed from 65.3 at four weeks to 81.6 at one year, confirming that repair matures progressively rather than resolving immediately post-injection.

The published clinical record for ChondroFiller is substantive — but it comes entirely from non-TMJ joints, and that gap is the central caveat of any discussion about jaw joint application. As of mid-2026, no published clinical series, manufacturer indication, or regulatory approval covers ChondroFiller use in the TMJ. This is currently an experimental, off-label application. The preclinical biological signals discussed in the preceding section may support scientific interest in future study, but they do not constitute clinical evidence of safety or efficacy in the jaw joint. Patients and clinicians considering this route should proceed on that basis.

Who is likely to be a suitable candidate

Patients most likely to be considered for a ChondroFiller injection in the TMJ share a specific clinical profile: a focal area of cartilage damage — typically Grade III or IV in severity — with structurally intact tissue around it. In practical terms, this means the damage is contained within a defined area rather than spread diffusely across the joint, and enough healthy architecture remains to support regenerative repair rather than wholesale reconstruction.

Conservative management should have been tried and found insufficient before this route is explored. Physiotherapy, oral splinting, and anti-inflammatory measures represent the appropriate first tier; ChondroFiller injection sits further along the pathway, for those who have not achieved adequate improvement through those means.

Patients with active joint infection, systemic inflammatory arthritis that is not well-controlled, or widespread degenerative change throughout the joint are likely to fall outside the suitable range. The procedure targets structural cartilage loss, not diffuse or end-stage disease.

Given how small and anatomically confined the TMJ is, image-guided placement by a clinician with specialist-level experience in this joint is essential — precision in a space this narrow demands considerably more than standard injection technique. Imaging to confirm defect morphology and rule out contraindications is a necessary part of any pre-procedure assessment; suitability is established through that evaluation, not before it.

Assessment and treatment at the London Cartilage Clinic

For patients in the London area who have reached this point in their research, the practical next step is a specialist assessment — not an injection. Given the experimental status of ChondroFiller injection in the TMJ and the anatomical precision the procedure demands, the clinical conversation needs to happen before any treatment decision is made.

Liquid Cartilage™ (ChondroFiller injection) is delivered in the UK at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads the clinical programme. An initial assessment covers defect morphology, current imaging, and overall joint health — the findings that determine whether a patient is a realistic candidate and, if so, how image-guided scaffold placement would be approached.

Patients considering this route can request an assessment at londoncartilage.com.

1. [1] Articular disk of the temporomandibular joint. https://en.wikipedia.org/?curid=9453896 https://en.wikipedia.org/?curid=9453896